CD8A and neoplasm: Among other anti-EphA10 monoclonal antibodies, clone #4 caused tumour regression and boosted the activation of CD8+ tumour-infiltrating cytotoxic T lymphocytes (CTLs) in vivo, while clone #9 triggered EphA10 internalisation in TNBC [135].